Antagonization of Heparin With Protamine Sulfate After TAVI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 940 participants.

Also called NCT06215378

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 940 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06215378
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06215378. Randomized; single masking; primary purpose treatment. Start 2025-05-25 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antagonization of Heparin With Protamine Sulfate After TAVI
Acronym
ATLANTIS-Prota
Condition
Aortic Valve Stenosis
Condition
Heart Valve Diseases
Intervention (Drug)
Antagonization of heparin with protamine sulfate
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Action Research Group (class: other)

Record details

Record id
cardio:ct-nct06215378
Content hash
f6c4a7240bd6e6b7f2c5782cc8d60dbf236f3c1f7ebf437de4e5b11ceeaf8d2d